Monoclonal Antibodies May No Longer Be a Match for Emerging COVID Strains

(MedPageToday) Evusheld, bebtelovimab losing potency as circulation of BQ.1, BQ.1.1 grows. Tixagevimab/cilgavimab (Evusheld) and bebtelovimab are likely ineffective against approximately 60% of currently circulating Omicron variants, creating a big gap in protection, particularly for immunocompromised individuals, researchers from a Harvard Medical School-led consortium said at a briefing on late last week.